Curis Reports Q1 Net Loss of $24.2M, Zero Revenue; Projects Conditional Cash Runway into H2 2027 Amid Delisting Threat
CRIS is trading near its 52-week low of $0.49 (12% above the low).
Summary
Curis announced a Q1 2026 net loss of $24.2 million and no revenue, with cash and equivalents of $15.0 million, projecting a conditional cash runway into H2 2027 based on future warrant exercises.
Key Events · Earnings and Guidance · CRIS
-
Significant Net Loss Reported
Curis reported a net loss of $24.2 million for the first quarter of 2026, a substantial increase from $10.6 million in the same period last year. This quarterly loss significantly exceeds the company's current market capitalization.
-
Zero Revenue in Q1 2026
The company recorded no revenue for Q1 2026, down from $2.4 million in Q1 2025, primarily due to the sale of Erivedge® royalties in Q4 2025.
-
Conditional Cash Runway Guidance
Curis projects its cash and cash equivalents of $15.0 million as of March 31, 2026, combined with an anticipated $20.2 million from the exercise of Series B warrants (contingent on a clinical milestone), should fund operations into the second half of 2027.
-
Increased Other Expenses
Other expense, net, increased significantly to $12.7 million in Q1 2026, primarily due to a change in the fair value of the warrant liability associated with the January 2026 PIPE Financing.
Analysis · CRIS · Life Sciences
Curis reported a substantial net loss for Q1 2026 that exceeds its current market capitalization, coupled with zero revenue, highlighting severe financial distress. While the company projects a cash runway into the second half of 2027, this is conditional on the exercise of Series B warrants, which are currently out-of-the-money and dependent on a clinical milestone. This update reinforces the 'going concern' warning from the prior 10-K and provides critical context following the recent Nasdaq delisting notice, indicating a highly precarious financial situation.
At the time of this filing, CRIS was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22M. The 52-week trading range was $0.49 to $3.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.